Olvanil

Olvanil

SCHEMBL537603

CCCCCCCCC=CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 7/20 1.00
HPGD P15428 3/20 1.00
MAPT P10636 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2D6 P10635 2/20 1.00
MEN1 O00255 1/20 1.00
TP53 P04637 1/20 1.00
MTOR P42345 1/20 1.00
KMT2A Q03164 1/20 1.00
ALDH1A1 P00352 2/20 0.90
CYP2C9 P11712 1/20 0.87
ALOX15 P16050 1/20 0.87
CYP2C19 P33261 1/20 0.87
BLM P54132 1/20 0.87
PMP22 Q01453 1/20 0.87
EPHX2 P34913 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10835242 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
SCHEMBL10710550 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
SCHEMBL10711981 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
Olvanil SCHEMBL557179 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
Olvanil SCHEMBL94262 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
SCHEMBL10713542 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
SCHEMBL10711036 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
Olvanil SCHEMBL29381897 1.00 TRPV1 (1.00) TRPV1HPGDMAPTCYP1A2CYP3A4
SCHEMBL10883574 0.98 TRPV1 (0.96) TRPV1HPGDMAPTCYP1A2CYP3A4
SCHEMBL10885299 0.98 TRPV1 (0.96) TRPV1HPGDMAPTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414427-A4 KAVALACTONE COMPOSITIONS AND METHODS OF USE SYNTA PHARMACEUTICALS CORP (US) 2004-08-18 EP claimed
EP-1414427-A2 KAVALACTONE COMPOSITIONS AND METHODS OF USE Kava Pharmaceuticals, Inc. (US) 2004-05-06 EP claimed
US-20030105159-A1 Kavalactone compositions and methods of use SYNTA PHARMACEUTICALS CORP. 2003-06-05 US claimed
WO-2003013436-A2 KAVALACTONE COMPOSITIONS AND METHODS OF USE KAVA PHARMACEUTICALS, INC. (US) 2003-02-20 WO claimed
US-5762963-A DISPERSING IN SOLID OR GEL VEHICLE IN WHICH CONCENTRATION OF CAPSAICINOID DECREASES FROM CENTER TOWARD PERIPHERY; FOR MOUTH, THROAT PAIN RELIEF EMORY UNIVERSITY (US) 1998-06-09 US claimed
WO-1996040079-A1 METHOD AND COMPOSITIONS FOR CONTROLLING ORAL AND PHARYNGEAL PAIN USING CAPSAICINOIDS EMORY UNIVERSITY (US) 1996-12-19 WO claimed
EP-0306060-B1 PHARMACEUTICAL PRODUCTS PROVIDING ENHANCED ANALGESIA THE PROCTER & GAMBLE COMPANY (US) 1992-08-19 EP claimed
EP-0149545-B1 PHARMACEUTICAL PRODUCTS PROVIDING ENHANCED ANALGESIA THE PROCTER & GAMBLE COMPANY (US) 1989-12-27 EP claimed
EP-0149544-B1 PHARMACEUTICAL PRODUCTS PROVIDING ENHANCED ANALGESIA THE PROCTER & GAMBLE COMPANY (US) 1989-09-13 EP claimed
US-4812446-A CAPSAICINOID AND SALICYLATE THE PROCTER & GAMBLE COMPANY (US) 1989-03-14 US claimed
EP-0306060-A2 Pharmaceutical products providing enhanced analgesia THE PROCTER & GAMBLE COMPANY (US) 1989-03-08 EP claimed
EP-0149545-A2 Pharmaceutical products providing enhanced analgesia THE PROCTER & GAMBLE COMPANY (US) 1985-07-24 EP claimed
US-20220288164-A1 METHOD TO INCREASE SYSTEMIC BLOOD PRESSURE IN SHOCK GEORGETOWN UNIVERSITY 2022-09-15 US disclosed
US-20210228511-A1 NEURONAL AGONISTS AND ISOTONIC OR HYPERTONIC SALINE FOR TREATING RESPIRATORY DISEASES UNIVERSITY OF SASKATCHEWAN (CA) 2021-07-29 US disclosed
US-20190038573-A1 ION CHANNEL ACTIVATORS AND METHODS OF USE CLIFF-CARTWRIGHT CORPORATION 2019-02-07 US disclosed
US-20180117004-A1 SELECTIVE ABLATION OF PAIN-SENSING NEURONS BY ADMINISTRATION OF A VANILLOID RECEPTOR AGONIST THE GOVERNMENT OF THE US SECRETARY OF THE DEPARTMENT OF (US) 2018-05-03 US disclosed
EP-0132115-A1 Novel compounds and compositions useful for producing analgesia THE PROCTER & GAMBLE COMPANY (US) 1985-01-23 EP disclosed
EP-0132114-A1 Novel compounds and compositions useful for producing analgesia THE PROCTER & GAMBLE COMPANY (US) 1985-01-23 EP disclosed
EP-0132113-A1 Compositions useful for producing analgesia THE PROCTER & GAMBLE COMPANY (US) 1985-01-23 EP disclosed
US-4493848-A N-((SUBSTITUTED PHENYL)METHYL)CIS MONOUNSATURATED ALKENAMIDE) THE PROCTER & GAMBLE COMPANY (US) 1985-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228511-A1 NEURONAL AGONISTS AND ISOTONIC OR HYPERTONIC SALINE FOR TREATING RESPIRATORY DISEASES CFTR, TRPV1, SLC18A3 TRPV1 2/4885HPGD 1641/4885MAPT 762/4885
US-20220288164-A1 METHOD TO INCREASE SYSTEMIC BLOOD PRESSURE IN SHOCK VASP, TRPV1, BDKRB2 TRPV1 2/4885HPGD 1178/4885MAPT 3809/4885
US-20180117004-A1 SELECTIVE ABLATION OF PAIN-SENSING NEURONS BY ADMINISTRATION OF A VANILLOID RECEPTOR AGONIST TRPV1, OPRL1, TRPV3 TRPV1 1/4885HPGD 1023/4885MAPT 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.